Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial

Richard E. Pratley; Christopher P. Cannon; David Z.I. Cherney; Francesco Cosentino; Darren K. McGuire; Margaret Noyes Essex; David Lawrence; Philip LStJ Jones; Jie Liu; Ingrid Adamsons; Samuel Dagogo‐Jack

doi:10.1016/s2666-7568(23)00032-6

March 29, 2023The Lancet Healthy LongevityOpen Access

Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate cardiorenal outcomes, kidney function changes, and overall safety with ertugliflozin treatment in older adults diagnosed with type 2 diabetes.
Secondary subgroup analysis of older participants enrolled in the VERTIS CV randomized, double-blind clinical trial.
Analyzed cardiorenal outcomes, renal function preservation, and adverse event profiles among older adults receiving ertugliflozin versus comparator.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized double-blind trial evaluates cardiorenal and kidney function outcomes of ertugliflozin in older adults with type 2 diabetes, indicating safety profiles in aging populations.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pratley et al. (2023) studied this question.

synapsesocial.com/papers/69df12429b582f29b9591706 https://doi.org/10.1016/s2666-7568(23)00032-6

View Full Paper

Ask AI

Bookmark

Share

Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading